Contaminant in the recalled unfractionated heparin preparations: where is the problem?
نویسندگان
چکیده
March 10, 2008/ 4:38 p.m. (EST): In a recently held press conference, the USFDA briefed the press that the potential contaminant in the recalled Baxter product is a heparin-like substance. The USFDA commented that utilizing high tech methods heparin-like molecules have been identified. No specifics regarding these contaminants were given. The Baxter personnel did not agree with this interpretation. The manufacturing process of heparin is such that other heparinlike contaminants such as the dermatan sulfate, heparin sulfate, and chondroitin sulfate are removed effectively. These represent the main contaminants in heparin.
منابع مشابه
Contaminants in heparins continue to be unfolded.
September 4, 2008; 1:00 p.m. (EST): Earlier this year several batches of heparins were initially recalled due to the increased prevalence of adverse reactions and deaths. Initially the US FDA recalled specific batches of heparin resulting in a total recall of Baxter’s unfractionated heparin. Since then Baxter has not reintroduced this product despite the fact that it had 50% of the total market...
متن کاملMass balance analysis of contaminated heparin product.
A quantitative analysis of a recalled contaminated lot of heparin sodium injection U.S. Pharmacopeia (USP) was undertaken in response to the controversy regarding the exact nature of the contaminant involved in the heparin (HP) crisis. A mass balance analysis of the formulated drug product was performed. After freeze-drying, a 1-ml vial for injection afforded 54.8±0.3 mg of dry solids. The exci...
متن کاملBiological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin
An unexpectedly high rate of adverse events and deaths were reported from November 2007 to April 2008 in patients exposed to heparin. Investigations on the quality of heparin revealed an oversulfated chondroitin sulfate (OSCS) contaminant in the heparin. Several reports on the chemical structure and limited biologic actions of OSCS have recently become available. However, no data are available ...
متن کاملComparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous Thromboembolism Following Major Obstetric-gynecological Surgeries: An Open-label Randomized Clinical Trial
Venous thromboembolism (VTE) occurs in about 5 percent of patients undergoing major abdominal surgeries. Prophylaxis of VTE is recommended using unfractionated heparin (UF) or low molecular weight heparin (LMWH) in high-risk patients. In spite of advantages and confirmed cost-effectiveness of LMWH, high costs of enoxaparin branded preparations limit its use. We aimed to compare the efficacy and...
متن کاملElectrocardiographic findings and global coronary risk assessment.
ment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97: 1702–7. [13] Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 668–98. [14] Fareed J, Jeskie W, Hoppensteadt D, Clarizo R, Walenga JM. Are the available low-molecular-weight heparin preparations the s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
دوره 14 3 شماره
صفحات -
تاریخ انتشار 2008